Hangzhou Hospital Staff Cohort

Westlake University

Overview

The Hangzhou Hospital Staff Cohort (HHSC) is a prospective cohort study among staffs from three hospitals located in Hangzhou, China, including the Hangzhou First People's Hospital, Hangzhou Women's Hospital, and Hangzhou Red Cross Hospital. Participants recruitment and baseline survey including anthropometric, lifestyle and clinical measurement, as well as biological samples collection are initiated in January 2021. Recruited hospital staff are followed up every year during the medical examination organized by their employer. The primary aim of the HHSC study is to investigate the prospective associations of diet, physical activities, sleep, and other lifestyle factors with the long-term metabolic health of the hospital staffs. The secondary aim of the HHSC study is to integrate multi-omics data including genomics, metabolomics, proteomics and microbiome by a machine learning algorithm, to probe into the complex mediating roles of gene, metabolism and gut microbiota linking lifestyle factors with metabolic health.

Study Type

OBSERVATIONAL

Conditions

Diabetes Mellitus Cardiovascular Diseases Metabolic Syndrome

Interventions

diet, physical activities, sleepOTHER

lifestyle factors

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Participants aged 18 years or older * Serving staffs of designated hospitals Exclusion Criteria: * Participants with cancer * Participants with other serious medical disorders

Locations (1)

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China

Outcomes

Primary Outcomes

Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L

Fasting blood glucose is measured every year during follow-up

Time frame: 3 years after enrollment

Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L

Fasting blood glucose is measured every year during follow-up

Time frame: 6 years after enrollment

Incidence of type 2 diabetes diagnosed as fasting blood glucose larger than 7.0 mmol/L

Fasting blood glucose is measured every year during follow-up

Time frame: 9 years after enrollment

Secondary Outcomes

Change of body mass index

Participants' body weight and height was measured to calculate body mass index every year during follow-up

Time frame: Change from baseline at 3 years

Change of body mass index

Participants' body weight and height was measured to calculate body mass index every year during follow-up

Time frame: Change from baseline at 6 years

Change of body mass index

Participants' body weight and height was measured to calculate body mass index every year during follow-up

Time frame: Change from baseline at 9 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.